TCA
WST icon

Trifecta Capital Advisors’s West Pharmaceutical WST Stock Holding History

Trifecta Capital Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8
Closed -$2.1K – 446
2025
Q3 		$2.1K Hold
8
– – ﹤0.01% 330
2025
Q2 		$1.75K Buy
+8
New +$1.71K ﹤0.01% 355
2024
Q1 		– Sell
-16
Closed -$5.63K – 443
2023
Q4 		$5.63K Buy
+16
New +$5.66K ﹤0.01% 244

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Trifecta Capital Advisors's WST Position: Q4 2025 in Review

Trifecta Capital Advisors sold out of West Pharmaceutical (WST) in Q4 2025, closing a stake of 8 shares — an estimated $2.1K sold.

Trifecta Capital Advisors first reported a position in WST in Q4 2023 and held it in 3 quarters. The position peaked at $5.63K in Q4 2023. 804 funds tracked by Wall St. Rank hold WST as of Q4 2025.

  • Trifecta Capital Advisors reported no remaining West Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Trifecta Capital Advisors sold 8 West Pharmaceutical shares in Q4 2025, an estimated $2.1K.
  • Trifecta Capital Advisors first reported a position in West Pharmaceutical in Q4 2023 and held it in 3 quarters.
  • Trifecta Capital Advisors's West Pharmaceutical position peaked at $5.63K in Q4 2023.
  • 804 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2025.

Based on Trifecta Capital Advisors's 13F filing for Q4 2025, filed 30 Jan 2026.